Expert Interview
A Second Look: Discussing Acadia Pharmaceuticals Daybue (trofinetide) in Rett Syndrome with a neurologist, in light of its recent FDA approval
Ticker(s): ACADInstitution: University of Alabama- Birmingham
- Professor of Pediatrics, Neurology, Neurobiology, Genetics, and Psychology at University of Alabama- Birmingham.
- Treats 250 patients per year with Rett Syndrome.
- Research is concentrated on rare diseases, principally related to Rett syndrome and mutations in the related gene, MECP2; principal investigator of the Office of Rare Disease and NICHD-funded Natural History Study for Rett.
What are your thoughts on the safety profile of Daybue and your key take aways from the Phase 3 trial?
Added By: sara_adminWhat percentage of your patients do you expect to prescribe Daybue to in the coming months?
Added By: sara_adminHave you had sales representatives from Acadia Pharmaceuticals reach out to you about the availability and timeline for the accessibility of Daybue for your patients?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
